美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Mace Security International, Inc.

0.0157

0.0000

成交量：- -

成交額：- -

市值：104.42萬

市盈率：-0.40

高：0.0157

開：0.0157

低：0.0157

收：0.0157

52周最高：0.0157

52周最低：0.0157

股本：6,659.61萬

流通股本：6,121.55萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.0391

每股收益(LYR):-0.0309

淨資產收益率：-106.94%

總資產收益率：-19.75%

市淨率：0.51

市盈率(LYR):-0.51

資料載入中...

總覽公司新聞資訊公告

減肥版司美格魯肽在中國獲批新適應症，系中國首個！減重藥為啥要管這件事？

未來已來，看口服司美如何重塑糖尿病的治療價值

告別針頭！口服司美格魯肽片實現16.6%體重減輕

不止減重，司美格魯肽亮出心血管獲益王牌

上半年創新藥對外授權近660億美元；司美格魯肽最新數據出爐

21世纪经济报道

在GLP-1（胰高血糖素樣肽-1）減肥藥的競爭中諾和諾德的司美格魯肽終於憑藉心血管方面的獲益扳回一局。9月1日記者從諾和

禮來Muvalaplin片啓動III期臨床適應症為降低伴Lp(a)水平升高患者MACE發生風險

復星醫藥、康方生物最新業績公布；勃林格殷格翰新藥獲批 | 動脈「醫」周報

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/MACE/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MACE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MACE\",,,,,undefined,":{"symbol":"MACE","market":"US","secType":"STK","nameCN":"Mace Security International, Inc.","latestPrice":0.01568,"timestamp":1771875780000,"preClose":0.01568,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":61215490,"shares":66596075,"eps":-0.039075,"marketStatus":"交易中","change":0,"latestTime":"02-23 14:43:00 EST 延時","open":0.01568,"high":0.01568,"low":0.01568,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.039075,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.01568,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MACE\",,,,,undefined,":{"symbol":"MACE","floatShares":61215490,"roa":"-19.75%","roe":"-106.94%","lyrEps":-0.030906,"shares":66596075,"dividePrice":0,"high":0.01568,"amplitude":0,"preClose":0.01568,"low":0.01568,"week52Low":0.01568,"pbRate":"0.51","psRate":"0.18","week52High":0.01568,"institutionHeld":0.0001,"latestPrice":0.01568,"eps":-0.039075,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.039075,"open":0.01568,"prevYearClose":0.01568,"prevWeekClose":0.0157,"prevMonthClose":0.0157,"prevQuarterClose":0.0157,"fiveDayClose":0.0157,"twentyDayClose":0.0157,"sixtyDayClose":0.0157},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MACE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-12-09","symbol":"MACE","reason":null,"defaultRemindTime":1733754600000,"announcedDate":"2024-12-06","type":"delisting","dateTimestamp":1733720400000},{"market":"US","date":"2024-09-30","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1727668800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-02","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1712030400000,"reportTimeType":"","actualEps":null},{"date":"2023-11-14","symbol":"MACE","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1699995600000,"name":null,"time":"盤後","dateTimestamp":1699938000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MACE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MACE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MACE\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593043353","title":"減肥版司美格魯肽在中國獲批新適應症，系中國首個！減重藥為啥要管這件事？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593043353","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593043353?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 21:56","pubTimestamp":1766411806,"startTime":"0","endTime":"0","summary":"2025年已近尾声，减重药赛道的竞争没有丝毫放松。就在今天（12月22日），司美格鲁肽注射液（商品名：诺和盈）的心血管适应症上市申请获得中国国家药品监督管理局（NMPA）批准，适用于降低已确诊为心血管疾病、且BMI≥27成人患者的主要心血管不良事件（心血管死亡、非致死性心肌梗死、非致死性卒中）的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598584460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MACE","BK4157","BK4183"],"gpt_icon":0},{"id":"2590518307","title":"未來已來，看口服司美如何重塑糖尿病的治療價值","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518307?lang=zh_tw&edition=fundamental","pubTime":"2025-12-10 16:37","pubTimestamp":1765355850,"startTime":"0","endTime":"0","summary":"第二代的长效及速效胰岛素联合应用，已成为糖尿病晚期管理的核心，但可能面临低血糖和体重增加等问题。“口服化”必然成为糖尿病治疗发展的新方向。在实现治疗便利性、且保证疗效的同时，口服司美格鲁肽在心血管保护和降低肾病风险方面的表现也引发业内关注。目前，2型糖尿病患者在降糖、降低心血管疾病及肾病风险方面的综合代谢治疗获益已经成为内分泌专业医生的治疗关注重点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MACE","BK4157","BK4183"],"gpt_icon":0},{"id":"2570909606","title":"告別針頭！口服司美格魯肽片實現16.6%體重減輕","url":"https://stock-news.laohu8.com/highlight/detail?id=2570909606","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570909606?lang=zh_tw&edition=fundamental","pubTime":"2025-09-25 17:10","pubTimestamp":1758791432,"startTime":"0","endTime":"0","summary":"结果显示：在严格遵循治疗的患者中，口服司美格鲁肽片25 mg组体重降幅达16.6%，显著高于安慰剂组的2.7%；34.4%的受试者减重超过20%，而安慰剂组这一比例仅为2.9%。即使考虑部分患者用药依从性不足的情况，口服组仍实现13.6%的体重降幅，近30%的患者减重超过20%。其中，司美格鲁肽注射液表现尤为突出，单季度销售额高达8.16亿元，占据市场主导地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925182127a4433b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925182127a4433b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4157","BK4599","LU1093756325.SGD","BK4007","MACE","BK4532","IE00BZ1G4Q59.USD","BK4585","BK4183","LU0154236417.USD","NVO","LU1093756168.USD","IE00BKVL7J92.USD","BK4588"],"gpt_icon":1},{"id":"2568459038","title":"不止減重，司美格魯肽亮出心血管獲益王牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2568459038","media":"药时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568459038?lang=zh_tw&edition=fundamental","pubTime":"2025-09-17 10:30","pubTimestamp":1758076249,"startTime":"0","endTime":"0","summary":"诺和诺德更是明确指出：诺和盈所展现的心脏保护获益是司美格鲁肽分子独有。事实上，司美格鲁肽在心血管保护方面的显著获益在机制研究阶段已有迹可循。该研究首次证实了诺和盈是全球首个在伴有确诊心血管疾病但无糖尿病的超重或肥胖成人中，显示出心血管结局获益的减重药物4。在全球范围内，每年约有2,100万人死于心血管疾病6。约有三分之二与肥胖相关的死亡与心血管疾病相关7,8。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091711560497979a96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091711560497979a96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999002232.USD","LU1066051225.USD","LU1585245621.USD","RCT","IE00BZ1G4Q59.USD","LU1061106388.HKD","LU0861579265.USD","IE00B2B36J28.USD","LU1162221912.USD","LU1057294990.SGD","LU0289739699.SGD","LU1291159041.SGD","LU1917777945.USD","IE00BSNM7G36.USD","LU0965509010.AUD","LU2023250504.SGD","LU2361044949.HKD","SG9999014575.USD","LU1035773651.USD","LU1934455863.HKD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","LU0985320562.USD","LU1934455277.USD","IE0009355771.USD","SG9999001176.SGD","LU1116320901.HKD","LU1069347547.HKD","SGXZ57979304.SGD","LU0122379950.USD","BK4585","LU1430594728.SGD","IE00B1BXHZ80.USD","LU1066053197.SGD","LU2324357040.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0208291251.USD","MRK","LU1929549753.HKD","BK4588","BK4599","LU1571399168.USD","LU2023250843.SGD","LU2468319806.SGD","MACE","BK4550","LU2089984988.USD","NVO","LU0203347892.USD"],"gpt_icon":1},{"id":"2564823056","title":"上半年創新藥對外授權近660億美元；司美格魯肽最新數據出爐","url":"https://stock-news.laohu8.com/highlight/detail?id=2564823056","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564823056?lang=zh_tw&edition=fundamental","pubTime":"2025-09-02 07:59","pubTimestamp":1756771151,"startTime":"0","endTime":"0","summary":"政策动向国家药监局副局长徐景和：上半年创新药对外授权金额近660亿美元9月1日，国家药监局副局长徐景和在2025年“全国药品安全宣传周”启动仪式上表示，即将收官的“十四五”，是持续释放政策红利的五年，医药产业创新发展更加有为、更加有力。2025年上半年创新药对外授权总金额已接近660亿美元，全球市场对中国创新药的认可度正在不断提升。地方上，去年共抽检药品216164批次，不合格率0.39%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902080149a4ae467f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902080149a4ae467f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","AD","LU1093756168.USD","Y","BK4585","BK4588","BK4183","O","BK4532","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4007","LU1093756325.SGD","LLY","BK4157","NVO","MACE","BK4132"],"gpt_icon":1},{"id":"2564807899","title":"在GLP-1（胰高血糖素樣肽-1）減肥藥的競爭中諾和諾德的司美格魯肽終於憑藉心血管方面的獲益扳回一局。9月1日記者從諾和","url":"https://stock-news.laohu8.com/highlight/detail?id=2564807899","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564807899?lang=zh_tw&edition=fundamental","pubTime":"2025-09-01 14:33","pubTimestamp":1756708413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4590","BK4183","LU0154236417.USD","GLP","LU1093756168.USD","NVO","MACE","IE00BZ1G4Q59.USD","BK4157","IE00BKVL7J92.USD","BK4585","BK4144","BK4007","BK4599","LU1093756325.SGD","BK4532","BK4588"],"gpt_icon":0},{"id":"2564898466","title":"禮來Muvalaplin片啓動III期臨床 適應症為降低伴Lp(a)水平升高患者MACE發生風險","url":"https://stock-news.laohu8.com/highlight/detail?id=2564898466","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564898466?lang=zh_tw&edition=fundamental","pubTime":"2025-09-01 12:31","pubTimestamp":1756701060,"startTime":"0","endTime":"0","summary":"本次试验主要目的为在伴有Lp水平升高且发生过ASCVD事件或发生首次ASCVD事件风险升高的成人参与者中评价Muvalaplin对主要不良心血管事件影响。Muvalaplin片为化学药物，适应症为在伴Lp水平升高且已确诊CVD或发生首次CVE风险升高的患者中，降低MACE的发生风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","LU2237443622.USD","SG9999018865.SGD","SGXZ81514606.USD","SG9999018857.SGD","IE00B2B36J28.USD","LU0097036916.USD","LU0114720955.EUR","LU0672654240.SGD","LU2461242641.AUD","LU1720051017.SGD","III","LU0238689110.USD","MACE","LU2552382215.SGD","SGXZ57979304.SGD","LU2237438978.USD","LU2750360997.AUD","LU0079474960.USD","LU2471134952.CNY","SGXZ51526630.SGD","LU0256863902.USD","LU2491050071.SGD","SGXZ99366536.SGD","LU0385154629.USD","LU0432979614.USD","LLY","LU0094547139.USD","LU0823434583.USD","LU0122379950.USD","LU2468319806.SGD","BK4599","LU0203201768.USD","LU2746668461.USD","LU0198837287.USD","LU1280957306.USD","LU2746668974.SGD","LU2602419157.SGD","BK4588","LU0354030511.USD","LU1366192091.USD","GB00BDT5M118.USD","LU0889565916.HKD","Y","LU0109391861.USD","LU2237443549.SGD","LU0466842654.USD","LU1548497426.USD","LU1974910355.USD","LU1267930730.SGD","LU0471298777.SGD"],"gpt_icon":1},{"id":"2563216290","title":"復星醫藥、康方生物最新業績公布；勃林格殷格翰新藥獲批 | 動脈「醫」周報","url":"https://stock-news.laohu8.com/highlight/detail?id=2563216290","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563216290?lang=zh_tw&edition=fundamental","pubTime":"2025-08-29 21:27","pubTimestamp":1756474020,"startTime":"0","endTime":"0","summary":"Daphne 作者：实习生陈川、郑奥、贺朵1国内企业动态新药进展三生制药个体化rhTPO方案疗效优于艾曲泊帕8月21日，中国医学科学院血液病医院张磊教授团队在《eClinicalMedicine》发表了“TE-ITP研究”成果。详细结果将于未来医学会议公布。财报数据复星医药发布2025半年报8月26日，复星医药发布2025年半年度业绩报告。和铂医药公布2025中期业绩8月27日，和铂医药公布其2025中期业绩。此次更新取消了此前要求患者必须确诊心血管疾病的条件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508292142309769fb28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508292142309769fb28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","LU0203202063.USD","LU0823434583.USD","LU1917777945.USD","SGXZ99366536.SGD","LLY","LU1548497426.USD","LU2361045086.USD","LU0323591593.USD","LU2491050154.USD","LU2264538146.SGD","LU1023059063.AUD","LU1366192091.USD","IE0002141913.USD","LU0109391861.USD","LU1974910355.USD","LU2552382132.HKD","LU0256863811.USD","BK4007","LU0122379950.USD","LU1267930730.SGD","LU2237443895.HKD","LU1868837300.USD","LU2471134952.CNY","LU2360106947.USD","BK4157","LU1551013425.SGD","LU2552382215.SGD","01801","IE0009355771.USD","LU2491049909.HKD","IE00BK4W5L77.USD","09926","09688","ITP","LU2456880835.USD","LU0097036916.USD","LU2602419157.SGD","LU2357305700.SGD","Y","LU0466842654.USD","LU1069344957.HKD","LU2471134879.HKD","LU0417517546.SGD","LU2746668461.USD","SGXZ51526630.SGD","01177","LU0094547139.USD","LU1720051108.HKD","LU1989771016.USD","HR","LU0882574139.USD","LU2112291526.USD","MACE","LU0198837287.USD","LU1061106388.HKD"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}